Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

C Campochiaro, E Della-Torre, G Cavalli… - European journal of …, 2020 - Elsevier
Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …
被引用次数：449 相关文章
[PDF] u-bordeaux.fr

[PDF][PDF] Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

C Campochiaro, E Della-Torre, G Cavalli… - European Journal of …, 2020 - umfcs.u-bordeaux.fr
ABSTRACT Background: Tocilizumab (TCZ), a humanized monoclonal antibody targeting
the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; …

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

C Campochiaro, E Della-Torre, G Cavalli… - European Journal of …, 2020 - ejinme.com
Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

C Campochiaro, E Della-Torre… - … journal of internal …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

C Campochiaro, E Della-Torre, G Cavalli… - European Journal of …, 2020 - hero.epa.gov
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective
cohort study | Health & Environmental Research Online (HERO) | US EPA Jump to main content …
[PDF] researchgate.net

[PDF][PDF] Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

C Campochiaro, E Della-Torre, G Cavalli, G De Luca… - researchgate.net
ABSTRACT Background: Tocilizumab (TCZ), a humanized monoclonal antibody targeting
the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; …
[HTML] nih.gov

[HTML][HTML] Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

C Campochiaro, E Della-Torre, G Cavalli… - European Journal of …, 2020 - ncbi.nlm.nih.gov
ABSTRACT Background: Tocilizumab (TCZ), a humanized monoclonal antibody targeting
the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; …

[引用][C] Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

C Campochiaro, E Della-Torre, G Cavalli… - European Journal of …, 2020 - cir.nii.ac.jp
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective
cohort study | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

C Campochiaro, E Della-Torre, G Cavalli… - EUROPEAN JOURNAL …, 2020 - iris.unisr.it
Background: Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.

C Campochiaro, E Della-Torre, G Cavalli… - European Journal of …, 2020 - europepmc.org
Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …